The study evaluates the safety and efficacy of Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients. The researchers hypothesize that additional Mesenchymal Stem Cell infusion can benefit the promising clinical islet transplantation through the following mechanisms: protection of islet from inflammatory damage, immunological modulation, engraftment promotion, thus decrease or eliminate the need of exogenous insulin and improve β-cell function.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
islet of allograft and MSCs of autograft
Fuzhou General Hospital
Fuzhou, Fujian, China
RECRUITINGExogenous insulin requirement
Time frame: 5
Hemoglobin A1c
Time frame: 5
Glucose and C-peptide levels
Time frame: 5
liver function
Time frame: 5
kidney function
Time frame: 5
Portal vein Ultrasound
Time frame: 1
autoantibodies
Time frame: 5
Complete Blood Count
Time frame: 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.